Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Ferrè

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|September 25, 2014
Recurrence of disease activity after repeated Natalizumab withdrawalsLaura Ferrè, Lucia Moiola, Francesca Sangalli, et al.
Journal of Neurology|April 7, 2023
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational studyChiara Zanetta, Maria A Rocca, Alessandro Meani, et al.
Frontiers in Neurology|April 19, 2024
Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in ItalyMassimo Filippi, Laura Ferrè, Chiara Zanetta, et al.
Frontiers in Neurology|March 10, 2022
<i>BDNF</i> Val66Met Polymorphism Is Associated With Motor Recovery After Rehabilitation in Progressive Multiple Sclerosis PatientsAntonino Giordano, Ferdinando Clarelli, Miryam Cannizzaro, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 25, 2020
Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosisLaura Ferrè, Andrea Mogavero, Ferdinando Clarelli, et al.
Pharmacogenomics|January 24, 2022
Transcriptional effects of fingolimod treatment on peripheral T cells in relapsing remitting multiple sclerosis patientsGiacomo Sferruzza, Ferdinando Clarelli, Elisabetta Mascia, et al.
European Journal of Neurology|April 17, 2021
Assessment of the genetic contribution to brain magnetic resonance imaging lesion load and atrophy measures in multiple sclerosis patientsFerdinando Clarelli, Maria Assunta Rocca, Silvia Santoro, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patientsFrancesca Sangalli, Lucia Moiola, Laura Ferrè, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 15, 2023
Risk HLA Variants Affect the T-Cell Repertoire in Multiple SclerosisMelissa Sorosina, Silvia Santoro, Laura Ferrè, et al.
Annals of Neurology|May 15, 2024
DNA Methylation in the Anti-Mullerian Hormone Gene and the Risk of Disease Activity in Multiple SclerosisAntonino Giordano, Béatrice Pignolet, Elisabetta Mascia, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|September 25, 2014
Recurrence of disease activity after repeated Natalizumab withdrawalsLaura Ferrè, Lucia Moiola, Francesca Sangalli, et al.
Journal of Neurology|April 7, 2023
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational studyChiara Zanetta, Maria A Rocca, Alessandro Meani, et al.
Frontiers in Neurology|April 19, 2024
Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in ItalyMassimo Filippi, Laura Ferrè, Chiara Zanetta, et al.
Frontiers in Neurology|March 10, 2022
<i>BDNF</i> Val66Met Polymorphism Is Associated With Motor Recovery After Rehabilitation in Progressive Multiple Sclerosis PatientsAntonino Giordano, Ferdinando Clarelli, Miryam Cannizzaro, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 25, 2020
Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosisLaura Ferrè, Andrea Mogavero, Ferdinando Clarelli, et al.
Pharmacogenomics|January 24, 2022
Transcriptional effects of fingolimod treatment on peripheral T cells in relapsing remitting multiple sclerosis patientsGiacomo Sferruzza, Ferdinando Clarelli, Elisabetta Mascia, et al.
European Journal of Neurology|April 17, 2021
Assessment of the genetic contribution to brain magnetic resonance imaging lesion load and atrophy measures in multiple sclerosis patientsFerdinando Clarelli, Maria Assunta Rocca, Silvia Santoro, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patientsFrancesca Sangalli, Lucia Moiola, Laura Ferrè, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 15, 2023
Risk HLA Variants Affect the T-Cell Repertoire in Multiple SclerosisMelissa Sorosina, Silvia Santoro, Laura Ferrè, et al.
Annals of Neurology|May 15, 2024
DNA Methylation in the Anti-Mullerian Hormone Gene and the Risk of Disease Activity in Multiple SclerosisAntonino Giordano, Béatrice Pignolet, Elisabetta Mascia, et al.
Pageof 3